Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.

[1]  H. Hricak,et al.  Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. , 1985, Radiology.

[2]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[3]  H. Zincke,et al.  Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. , 1990, The Journal of urology.

[4]  D. Mendelson,et al.  Comparison of MRI and CT for study of renal and perirenal masses. , 1991, Critical reviews in diagnostic imaging.

[5]  D. Lim,et al.  Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. , 1993, The Journal of urology.

[6]  H. Herr.  Partial nephrectomy for incidental renal cell carcinoma. , 1994, British journal of urology.

[7]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Seaman,et al.  Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. , 1996, Urology.

[9]  R. Fisher,et al.  Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. , 1997, The cancer journal from Scientific American.

[10]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[11]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[12]  M Jayson,et al.  Increased incidence of serendipitously discovered renal cell carcinoma. , 1998, Urology.

[13]  P. Russo,et al.  Surgical management of renal tumors 4 cm. or less in a contemporary cohort. , 2000, The Journal of urology.

[14]  H. Moch,et al.  Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma , 2000, Cancer.

[15]  R. Cestari,et al.  Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). , 2000, Urology.

[16]  E. Fishman,et al.  Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  R. Figlin,et al.  Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. , 2001, The Journal of urology.

[18]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[19]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[20]  R. Coleman,et al.  The skeletal metastatic complications of renal cell carcinoma. , 2001, International journal of oncology.

[21]  A. Minervini,et al.  Prognostic value of nuclear grading in patients with intracapsular (pT1‐pT2) renal cell carcinoma , 2002, Cancer.

[22]  Vicente E. Torres,et al.  Matched comparison of radical nephrectomy vs. nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. , 2002 .

[23]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Bokemeyer,et al.  The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience , 2002, BJU international.

[25]  A. Lipton,et al.  Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma , 2003, Cancer.

[26]  R. Figlin,et al.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma , 2003, Cancer.

[27]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[28]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[29]  P. Choyke,et al.  Hereditary renal cancers. , 2003, Radiology.

[30]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[31]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Janetschek,et al.  Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. , 2004, Urology.

[33]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[34]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[35]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[36]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[37]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[38]  J. Cheville,et al.  A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. , 2004, The Journal of urology.

[39]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[40]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Cheville,et al.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. , 2004, The Journal of urology.

[42]  A. Billis.  Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[43]  J. Cheville,et al.  Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. , 2005, The Journal of urology.

[44]  S. Horvath,et al.  Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma , 2005, Cancer.

[45]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Israel,et al.  How I do it: evaluating renal masses. , 2005, Radiology.

[47]  Jeffrey W. Clark,et al.  Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.

[48]  U. Jonas,et al.  The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. , 2005, European urology.

[49]  J. Cheville,et al.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2005, Cancer.

[50]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[51]  F. Guillé,et al.  Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma , 2005, Cancer.

[52]  A. Oza,et al.  Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  N. Rioux-Leclercq,et al.  Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Piccart,et al.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.

[56]  M. Gordon.  Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma , 2006 .

[57]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[58]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Russo,et al.  Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  David C. Miller,et al.  Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. , 2006, Urology.

[62]  J. Lam,et al.  Open partial nephrectomy for the treatment of renal cell carcinoma , 2006, Current urology reports.

[63]  S. Naito,et al.  Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.

[64]  M. Blute.  Sunitinib in patients with metastatic renal cell carcinoma , 2006 .

[65]  P. Russo,et al.  Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm , 2006, BJU international.

[66]  E. Small,et al.  A phase II study of gemcitabine and capecitabine in metastatic renal cancer , 2006, Cancer.

[67]  M. Srougi,et al.  Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor , 2007, BJU international.

[68]  A. Hindmarsh,et al.  Randomized trial of laparoscopic v open nephrectomy. , 2007, Journal of endourology.

[69]  A. Hemal,et al.  Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. , 2007, The Journal of urology.

[70]  Louis R Kavoussi,et al.  Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. , 2007, The Journal of urology.

[71]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[72]  R. Ghavamian,et al.  Renal medullary carcinoma: the Bronx experience. , 2007, Urology.

[73]  F. Guillé,et al.  Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. , 2007, The Journal of urology.

[74]  N. Rioux-Leclercq,et al.  Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.

[75]  F. Guillé,et al.  Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. , 2007, European urology.

[76]  Chao-yuan Huang,et al.  Long-term follow-up of hand-assisted laparoscopic radical nephrectomy for organ-confined renal cell carcinoma. , 2007, Urology.

[77]  A. Billis,et al.  Renal medullary carcinoma: report of seven cases from Brazil , 2007, Modern Pathology.

[78]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[79]  M. Srougi,et al.  Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. , 2007, The Journal of urology.

[80]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[82]  M. Stifelman,et al.  A matched‐cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses , 2007, BJU international.

[83]  R. Uzzo,et al.  Cryoablation or radiofrequency ablation of the small renal mass , 2008, Cancer.

[84]  T. Choueiri,et al.  Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma , 2008, Cancer.

[85]  B. Rini,et al.  A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab , 2008 .

[86]  U. Treiber,et al.  Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. , 2008, European journal of cancer.

[87]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[88]  Stephen A Boorjian,et al.  Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. , 2008, The Journal of urology.

[89]  A. Hemal,et al.  A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma , 2009, World Journal of Urology.

[90]  P. Thall,et al.  A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. , 2008, The Journal of urology.

[91]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[92]  A. Shalhav,et al.  Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. , 2008, Journal of endourology.

[93]  H. Heinzer,et al.  Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. , 2008, European urology.

[94]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[95]  B. Lane,et al.  Active surveillance of renal masses in elderly patients. , 2008, The Journal of urology.

[96]  G. Sonpavde,et al.  Axitinib for renal cell carcinoma , 2008, Expert opinion on investigational drugs.

[97]  P. Russo,et al.  Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. , 2009, The Journal of urology.

[98]  L. Kavoussi,et al.  Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. , 2009, The Journal of urology.

[99]  A. Ravaud,et al.  Sequential sorafenib and sunitinib for renal cell carcinoma. , 2009, The Journal of urology.

[100]  B. Lane,et al.  Management of the adrenal gland during partial nephrectomy. , 2009, The Journal of urology.

[101]  J. Kaouk,et al.  Guideline for management of the clinical T1 renal mass. , 2009, The Journal of urology.

[102]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Victoria Y. Bird,et al.  Management of renal masses with laparoscopic-guided radiofrequency ablation versus laparoscopic partial nephrectomy. , 2009, Journal of endourology.

[104]  R. Figlin,et al.  Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.

[105]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  I. Gill,et al.  Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. , 2009, Urology.

[107]  Jong Wook Park,et al.  Significance of 18F‐fluorodeoxyglucose positron‐emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma , 2009, BJU international.

[108]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  B. Lindgren,et al.  Sequential therapy with sorafenib and sunitinib in renal cell carcinoma , 2007, Cancer.

[110]  F. Saad,et al.  Radical versus partial nephrectomy , 2009, Cancer.

[111]  A. Ravaud,et al.  First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  M. Gordon.  Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma , 2009 .

[113]  E. Thiel,et al.  Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib , 2009, Oncology.

[114]  B. Delahunt,et al.  Uncommon and recently described renal carcinomas , 2009, Modern Pathology.

[115]  W. Roberts,et al.  Patient and pathologic correlates with perioperative and long-term outcomes of laparoscopic radical nephrectomy. , 2009, Urology.

[116]  M. Blute,et al.  The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses , 2009 .

[117]  M. Rouprêt,et al.  Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. , 2009, The Journal of urology.

[118]  J. Milner,et al.  The role of cytoreductive nephrectomy in the era of molecular targeted therapy , 2009, International journal of urology : official journal of the Japanese Urological Association.

[119]  R. Uzzo,et al.  Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[120]  D. Jacqmin,et al.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.

[121]  L. Kavoussi,et al.  Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention , 2009, BJU international.

[122]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  F. Zhou,et al.  Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy , 2010, World Journal of Urology.

[124]  Y. Funahashi,et al.  Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. , 2009, European urology.

[125]  S. Taneja,et al.  The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. , 2009, The Journal of urology.

[126]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  R. Autorino,et al.  Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[129]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  J. Cheville,et al.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. , 2010, The Journal of urology.

[131]  B. Rini,et al.  Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab , 2010, Cancer.

[132]  F. Kim,et al.  7-year oncological outcomes after laparoscopic and open partial nephrectomy , 2010 .

[133]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[134]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  J. Kaouk,et al.  Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older , 2010, Cancer.

[136]  E. Jonasch,et al.  Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. , 2010 .

[137]  B. Lane,et al.  Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. , 2010, European urology.

[138]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[139]  V. Reuter,et al.  Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma , 2012, Investigational New Drugs.

[140]  V. Margulis,et al.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? , 2010, Cancer.

[141]  J. Kaouk,et al.  Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. , 2010, Urology.

[142]  E. Fokas,et al.  Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole-Brain Radiotherapy Be Added to Stereotactic Radiosurgery? , 2010, Strahlentherapie und Onkologie.

[143]  T. Christmas,et al.  Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[145]  J. Dutcher,et al.  Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy , 2011, Medical oncology.

[146]  T. Olencki,et al.  Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  P. Ramchandani,et al.  Comparison of radiographical imaging modalities for measuring the diameter of renal masses: is there a sizeable difference? , 2011, BJU international.

[148]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[149]  E. Jonasch,et al.  Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  P. Russo,et al.  Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. , 2011, The Journal of urology.

[151]  J. Patard,et al.  Lymph node dissection in renal cell carcinoma. , 2011, European urology.

[152]  C. Bokemeyer,et al.  Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[153]  T. Choueiri,et al.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.

[154]  T. Choueiri,et al.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. , 2011, Hematology/oncology clinics of North America.

[155]  R. Uzzo,et al.  Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.

[156]  J. Ahn,et al.  Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[157]  C. Reddy,et al.  The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. , 2012, Practical radiation oncology.

[158]  C. Blank,et al.  Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  C. Porta,et al.  Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  John L. Gore,et al.  Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. , 2012, JAMA.

[161]  R. Shah,et al.  Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship , 2012, The American journal of surgical pathology.

[162]  Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology. , 2012 .

[163]  R. Thompson,et al.  Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. , 2012, The Journal of urology.

[164]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[165]  J. Mechalakos,et al.  Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. , 2012, International journal of radiation oncology, biology, physics.

[166]  W. Linehan,et al.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. , 2012, The oncologist.

[167]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[168]  S. Joniau,et al.  Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions , 2013, Drugs & Aging.

[169]  G. Scagliotti,et al.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors , 2014, Supportive Care in Cancer.

[170]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[171]  R. Millikan,et al.  Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. , 2013, European journal of cancer.

[172]  R. Motzer,et al.  Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. , 2013, Clinical genitourinary cancer.

[173]  R. Motzer,et al.  Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial , 2013, British Journal of Cancer.

[174]  Robert J. Jones,et al.  Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma , 2013, BMC Urology.

[175]  E. Jonasch,et al.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. , 2013, The Lancet. Oncology.

[176]  J. Hainsworth,et al.  Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. , 2013, Clinical genitourinary cancer.

[177]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[178]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[179]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[180]  E. Heath,et al.  The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  I. Derweesh,et al.  Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors , 2014, Current opinion in urology.

[182]  Tae Min Kim,et al.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  R. Motzer,et al.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  J. Cheville,et al.  Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  J. Himmelfarb,et al.  Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .

[186]  W. Linehan,et al.  Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  R. Motzer,et al.  Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial , 2014, British Journal of Cancer.

[188]  Hongzhe Shi,et al.  Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma , 2015, Asia-Pacific journal of clinical oncology.

[189]  C. Porta,et al.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.

[190]  J. Hainsworth,et al.  Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). , 2015 .

[191]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[192]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[193]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[194]  S. Signoretti,et al.  Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma , 2015, Cancer.

[195]  A. Ravaud,et al.  Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. , 2016 .

[196]  P. Tamboli,et al.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.

[197]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[198]  R. Motzer,et al.  CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). , 2016 .

[199]  R. Motzer,et al.  Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. , 2016, The Lancet. Oncology.

[200]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[201]  T. Choueiri,et al.  First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2016, European journal of cancer.

[202]  S. Buti,et al.  First‐Line PAzopanib in NOn–clear‐cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study , 2017, Clinical genitourinary cancer.